These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35840465)

  • 21. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.
    Thompson IM; Ankerst DP; Chi C; Lucia MS; Goodman PJ; Crowley JJ; Parnes HL; Coltman CA
    JAMA; 2005 Jul; 294(1):66-70. PubMed ID: 15998892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
    Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
    J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate carcinoma screening in the county of Tyrol, Austria: experience and results.
    Reissigl A; Horninger W; Fink K; Klocker H; Bartsch G
    Cancer; 1997 Nov; 80(9):1818-29. PubMed ID: 9351555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Re-examining Prostate-specific Antigen (PSA) Density: Defining the Optimal PSA Range and Patients for Using PSA Density to Predict Prostate Cancer Using Extended Template Biopsy.
    Jue JS; Barboza MP; Prakash NS; Venkatramani V; Sinha VR; Pavan N; Nahar B; Kanabur P; Ahdoot M; Dong Y; Satyanarayana R; Parekh DJ; Punnen S
    Urology; 2017 Jul; 105():123-128. PubMed ID: 28431993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
    Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA
    Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.
    Horninger W; Cheli CD; Babaian RJ; Fritsche HA; Lepor H; Taneja SS; Childs S; Stamey TA; Sokoll LJ; Chan DW; Brawer MK; Partin AW; Bartsch G
    Urology; 2002 Oct; 60(4 Suppl 1):31-5. PubMed ID: 12384160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elevated IsoPSA Selects for Clinically Significant Prostate Cancer Without a Preference for Any Particular Adverse Histopathologic or Radiographic Feature.
    Benidir T; Hofmann M; Lone Z; Nguyen JK; Purysko AS; Stovsky M; Klein EA; Weight CJ
    Urology; 2022 Oct; 168():150-155. PubMed ID: 35680047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A; Dworschack RT; Partin AW
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics.
    Miller MC; O'Dowd GJ; Partin AW; Veltri RW
    Urology; 2001 Jun; 57(6):1105-11. PubMed ID: 11377319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate-specific antigen/solvent interaction analysis: a preliminary evaluation of a new assay concept for detecting prostate cancer using urinary samples.
    Stovsky M; Ponsky L; Vourganti S; Stuhldreher P; Siroky MB; Kipnis V; Fedotoff O; Mikheeva L; Zaslavsky B; Chait A; Jones JS
    Urology; 2011 Sep; 78(3):601-5. PubMed ID: 21783231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate cancer screening in the fit Chilean elderly: a head to head comparison of total serum PSA versus age adjusted PSA versus primary circulating prostate cells to detect prostate cancer at initial biopsy.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Jacob O
    Asian Pac J Cancer Prev; 2015; 16(2):601-6. PubMed ID: 25684494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical usefulness of free PSA in early detection of prostate cancer.
    Luboldt HJ; Swoboda A; Börgermann C; Fornara P; Rübben H;
    Onkologie; 2001 Feb; 24(1):33-7. PubMed ID: 11441278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensity-focused ultrasound focal therapy for localized prostate cancer.
    Dickinson L; Ahmed HU; Hindley RG; McCartan N; Freeman A; Allen C; Emberton M; Kirkham AP
    Urol Oncol; 2017 Jan; 35(1):30.e9-30.e15. PubMed ID: 27663393
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial.
    Djavan B; Remzi M; Zlotta AR; Ravery V; Hammerer P; Reissigl A; Dobronski P; Kaisary A; Marberger M
    Urology; 2002 Oct; 60(4 Suppl 1):4-9. PubMed ID: 12384156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate cancer detection by prostate-specific antigen-related parameters.
    Segawa N; Gohji K; Iwamoto Y; Ueda H; Katsuoka Y
    Hinyokika Kiyo; 2003 Jul; 49(7):405-10. PubMed ID: 12968483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Free/total PSA ratio improves differentiation of benign and malignant disease of the prostate: critical analysis of two different test populations.
    Veltri RW; Miller MC
    Urology; 1999 Apr; 53(4):736-45. PubMed ID: 10197849
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.
    Partin AW; Brawer MK; Bartsch G; Horninger W; Taneja SS; Lepor H; Babaian R; Childs SJ; Stamey T; Fritsche HA; Sokoll L; Chan DW; Thiel RP; Cheli CD
    J Urol; 2003 Nov; 170(5):1787-91. PubMed ID: 14532777
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Performance of Prostate Health Index in Biopsy Naïve Black Men.
    Babajide R; Carbunaru S; Nettey OS; Watson KS; Holloway-Beth A; McDowell T; Ben Levi J; Murray M; Stinson J; Hollowell CMP; Dalton DP; Moore L; Kittles RA; Gann PH; Schaeffer EM; Murphy AB
    J Urol; 2021 Mar; 205(3):718-724. PubMed ID: 33103942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate cancer screening in the Tyrol, Austria: experience and results.
    Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
    Eur J Cancer; 2000 Jun; 36(10):1322-35. PubMed ID: 10882875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.